Parkinson's and MSA study with biosamples and imaging
Part of Brain & nervous system clinical trials.
This study collects data from people with Parkinson's disease or multiple system atrophy (MSA) to better understand these conditions. You will have blood, saliva, optional spinal fluid tests, and brain scans (MRI, PET/SPECT).
Summary written for real people, not researchers, by Clin2.
Who can take part
- Must have a doctor-confirmed diagnosis of Parkinson's disease or multiple system atrophy (MSA).
- Must be willing to provide blood, saliva, and optional spinal fluid samples.
- Must be able to undergo brain scans (MRI, PET/SPECT).
- Cannot have had a stroke, head injury, brain tumor, or brain surgery.
- Cannot have severe mental health conditions like uncontrolled depression or schizophrenia.
- Cannot have other serious health problems that would affect study participation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This is an early-stage study testing a new experimental medicine called SST001 in people with Parkinson's disease (PD) and multiple system atrophy (MSA), as well as healthy volunteers. The study checks whether SST001 is safe, how the body processes it, and where it goes in the body using imaging scans.
This study uses brain scans and clinical check-ins to better diagnose and predict how Parkinson-related conditions may progress over time. It may help researchers find markers that explain why symptoms change, and could improve future care.
This study is collecting information from patients with multiple system atrophy (a rare neurological condition affecting movement and body functions), Parkinson disease, and healthy volunteers to better understand these conditions. By participating, you help doctors learn more about how these diseases develop and progress.
This study looks at genetic factors in people with PSP, CBS, MSA, or similar brain conditions, and also in their family members. It involves genetic testing to learn more about these diseases and may help find new treatments.
This study uses brain scans (PET, and possibly spinal fluid) to measure changes linked to “synaptic loss” in people with multiple system atrophy (MSA) or progressive supranuclear palsy (PSP). It may help researchers understand disease changes and how they relate to symptoms, which could guide future treatments.
This trial uses a new imaging agent (like a dye) to see signs of Parkinson's disease in the brain. If you have Parkinson's or a related condition like Lewy body dementia or multiple system atrophy, this scan may help researchers better understand these illnesses.
Hear when a new Multiple System Atrophy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.